The INTerpath-001 trial randomized 1,137 patients with resected stage IIB to IV melanoma to Keytruda alone or Keytruda plus ...
A personalised cancer vaccine developed by Moderna and Merck shows promise in reducing melanoma metastasis risk by 38% using ...
A study of a personalized vaccine combined with an existing immunotherapy found the treatment helped patients with melanoma avoid cancer recurrence. The combination trains the patient's immune system ...
When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each ...
1d
Doctors call Moderna, Merck cancer vaccine data a major advancement — despite Wall Street reaction
Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma ...
Six melanoma specialists described Moderna and Merck's personalized cancer vaccine results as clinically meaningful and ...
The vaccine, called intismeran, is tailored to each patient’s tumour. The findings, which measured recurrence risk over two ...
Moderna aur Merck ke shares gire jab vaccine trial data ne sirf **42%** recurrence reduction dikhaya. Investors ki badhi ...
Moderna and Merck stocks fell as new melanoma vaccine trial data showed a 42% recurrence reduction, missing investor ...
The vaccine was custom-brewed for each patient to match their tumor. Adding it to a standard post-surgery treatment reduced ...
The results, which triggered Moderna’s stock to drop, are “really encouraging,” says Karen Knudsen, CEO of the Parker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results